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ABSTRACT
Creatine and carnosine have been considered as valuable nutraceuticals in meat
products for a long time. Creatine as energy buffer plays an important role in cellular
metabolism and shows protective effects in neurodegenerative diseases such as Parkinson’s
disease and Huntington’s disease. Carnosine has multiple physiological functions associated
with anti-oxidation and anti-aging. Although creatine and carnosine can be synthesized
endogenously in human, studies show health benefits of creatine and carnosine
supplementation. Because creatine and carnosine exist naturally only in animal muscle and
brain tissues, meat is an important source of dietary creatine and carnosine. Few studies,
however, have focused on beef creatine and carnosine contents and the factors influencing
their concentrations.
The objective of this study was to investigate the variation of creatine and carnosine
contents in longissimus muscle of Angus cattle and their correlations with carcass and
palatability traits. Longissimus muscle samples were collected from 2,342 Angus cattle fed in
Iowa (n=1,114), Texas (n=455), Colorado (n=391), and California (n=382). Creatine,
creatinine, carnosine, and anserine were extracted from beef and quantified by
high-performance liquid chromatography. The concentrations of these four compounds then
were correlated with carcass and palatability traits including hot carcass weight (HCW),
kidney pelvic heart (KPH) fat percentage, ribeye area, fat thickness, marbling score,
calculated yield grade, sensory panel scores, Warner Bratzler shear force (WBSF), and
thiobabituric acid reactive substances (TBARS).
Statistical analysis showed that the gender of cattle significantly (P < 0.05) affected the
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concentrations of creatine, creatinine, carnosine and anserine. Bulls contained greater
creatine content than did steers (P < 0.05) but produced lower amount of carnosine than did
heifers (P < 0.05). Significant variation from feeding location was also observed. The
correlations with carcass quality and sensory scores were significant but weak, which
suggested that beef quality, especially tenderness, juiciness, and flavor, would not be strongly
affected by selecting for higher creatine and carnosine contents.
1THESIS ORGANIZATION
This thesis is presented in the form of one complete manuscript for submission to the
Journal of Animal Science as a partial fulfillment of the requirements for a Master of Science
degree. The title of the paper is “Concentrations of creatine, creatinine, carnosine, and
anserine in bovine longissimus muscle and their correlations with carcass and palatability
traits” It is formatted according to the requirement of the journal, with an abstract,
introduction, materials and methods, results and discussion, implication, and references. The
manuscript is preceded by a literature review section and followed by a general summary
section. The general literature review introduces background information of the topics
discussed in the manuscript. The summary section provides discussion about general
conclusions and future research.
2CHAPTER 1
GENERAL INTRODUCTION
Creatine and creatinine
I. Structure information
Creatine (Cr) (2-(1-methylcarbamimidamido) acetic acid) is a nitrogenous organic acid
that exists naturally in vertebrates and plays an important role in cellular energy metabolism
by interconversion to its high-energy phosphorylated analogue phosphocreatine (PCr).
Creatine is in equilibrium with its spontaneously formed cyclic derivative creatinine (Crn)
(2-amino-1-methyl-1H-imidazol-4-ol) in solution. In vivo, the conversion of Cr to Crn is
irreversible and at an almost constant rate. Creatinine is excreted through urine. The chemical
structures of Cr, PCr and Crn are shown at Figure 1.
Figure 1. Chemical structures of creatine, phosphocreatine, and creatinine. (Adopted from
Wyss et al, 2000)
3II. Creatine kinase reaction
Cr/PCr/CK system functions as a shuttle of high-energy phosphate between sites of
ATP production and ATP consumption in tissues with high and fluctuating energy demand
such as muscle, heart and brain (Wallimann et al., 1992; Wyss and Kaddurah-Daouk, 2000).
In higher vertebrates, four creatine kinase (CK) isoforms with specific functions have been
found. They are named on the basis of tissue expression and subcellular distribution: two in
muscle, muscle cytosolic isoform (M-CK) and sarcomeric mitochondrial isoform (sMtCK);
two in brain, brain cytosolic isoform (B-CK) and ubiquitous mitochondrial isoform (uMtCK)
(Beard and Braissant, 2010; Wyss and Schulze, 2002). As shown in Figure 2, the
mitochondria creatine kinases consume ATP to convert Cr to its high-energy counterpart PCr
for export to cytosol. The cytosolic creatine kinases dephosphorylate PCr and convert ADP
to ATP for energy consumption.
Tissues with Cr/PCr/CK system (such as muscle, heart, and brain) have several
advantages compared with tissues relying solely on ATP/ADP system, such as liver. First,
PCr and Cr, relative to ATP and ADP, are smaller and less negatively charged. They can
accumulate to much higher intracellular concentrations and have a faster diffuse coefficients
than ATP and ADP (Wyss and Kaddurah-Daouk, 2000). Meanwhile, the free energy change
(ΔG°′) (pH 7.0) of PCr hydrolysis is −45.0 kJ/mol compared with −31.8 kJ/mol for ATP,
allowing Cr/PCr/CK system with a higher level of phosphorylation buffering ability
(Schlattner, 2003). Finally, by stabilizing cellular ATP/ADP ratio, the Cr/PCr/CK system
4also may protect the cell from unnecessary trigger of multiple metabolic responses
(Schlattner, 2003; Wyss and Kaddurah-Daouk, 2000).
Figure 2. Creatine kinase reaction. The mitochondria creatine kinases (MtCK) consume
ATP to convert Cr to its high-energy counterpart PCr for export to cytosol. The cytosolic
creatine kinase (CK) dephosphorylates PCr and converts ADP to ATP for energy
consumption. (Adopted from Beard and Braissant, 2010)
5III. Creatine metabolism
A 70 kg young man contains approximately 120 g total Cr (Cr+PCr) (Schulze, 2003).
More than 90% of Cr is distributed in muscle tissue. In human, Cr can be absorbed by small
intestine, mainly from food such as fresh meat, fish, and dairy products. Beef is a good
source of dietary Cr compared with other meat products. In the study of Pais et at. (1999)
who investigated Cr contents in beef, chicken breast, chicken thigh, turkey breast, and fish,
the highest Cr concentration (6.33 mg/g) was observed in beef top round steak.
Creatine also can be synthesized endogenously, primarily in kidney, pancreas, and
liver (Schlattner, 2003; Wyss and Schulze, 2002). Two enzymes are essential for Cr
biosynthesis, arginine: glycine amidinotransferase (AGAT) and S-adenosyl-L-methionine:
N-guanidinoacetate methyltransferase (GAMT). The biosynthesis pathway is shown in
Figure 3. AGAT transfers amidino group of arginine (limiting factor) to glycine and produces
ornithine and guanidino acetate (GAA) in kidney. This reaction is regulated by Cr through a
negative feedback loop in AGAT gene transcription. GAA then is methylated at the amidino
group by GMAT using S-adenosyl-L-methionine to yield Cr and S-adenosyl-homocysteine in
liver (Beard and Braissant, 2010; Schulze, 2003; Wyss and Kaddurah-Daouk, 2000). Growth
hormone, thyroid hormone, and sex hormones were reported to modulate Cr endogenous
synthesis through increasing expression of AGAT and GAMT (Guthmiller et al., 1994; Lee
et al., 1994). Creatine is in equilibrium with its spontaneously formed cyclic derivative
creatinine (Crn) in solution. Creatinine can be excreted through urine. In vivo, the conversion
6of Cr to Crn is irreversible and at constant rate (Wyss and Kaddurah-Daouk, 2000).
Figure 3. Creatine metabolism. Arginine: glycine amidinotransferase (AGAT) transfers
amidino group of arginine (limiting factor) to glycine and produces ornithine and guanidino
acetate (GAA) in kidney. GAA is then methylated at the amidino group by
N-guanidinoacetate methyltransferase (GAMT) using S-adenosyl methionine to yield Cr and
S-adenosyl homocysteine in liver. Creatine is transported by a member of the solute carrier
family 6, SLC6A8. Creatine is in equilibrium with its spontaneously formed cyclic derivative
creatinine. Creatinine can be excreted through urine. (Adopted from Schulze, 2003)
7Creatine transport through blood to high energy demanding tissues involves a member
of the solute carrier family 6, SLC6A8. SLC6A8 can transport Cr against a large
concentration gradient (plasma [Cr] ~50 uM and intracellular [Cr+PCr] up to 40 mM) with
co-transport of two Na+ and one Cl- (Guimbal and Kilimann, 1993). The transport is driven
by sodium gradient established by Na+/K+ -ATPase. SLC6A8 expression is found in
microcapillary endothelial cells at blood-brain barrier (BBB), which suggests that the BBB
has at least limited permeability for peripheral Cr (Braissant, 2010).
IV. Creatine deficiency syndromes
AGAT, GAMT, and SLC6A8 genes are mapped at chromosome 15q11.2, 19p13.3 and
Xq28, respectively (Schulze, 2003). Mutations in AGAT, GAMT, and SLC6A8 genes cause
inborn error of metabolism, called Cr deficiency syndromes (Braissant, 2010). AGAT and
GAMT deficiencies are autosomal recessive disorders, whereas SLC6A8 deficiency is an
X-linked disease. Creatine deficiency syndromes are considered among the most common
inborn errors of metabolism with the prevalence of all three Cr deficiencies being estimated
at 2.7% of all mental retardation (Schulze, 2003). The prevalence of SLC6A8 deficiency was
estimated at 2% of all X-linked mental retardations and 1% of mental retardation with
unknown etiology in males (Schulze, 2003). Compared with SLC6A8, AGAT and GAMT
deficiencies happen relatively rarer. The common phenotypes in all three disorders are almost
complete lack of Cr in brain and neurological symptoms such as mental retardation,
8developmental arrest, and delays in speech acquisition or epilepsy. GAMT deficiency also
shows accumulation of the neurotoxic product GAA because of the lack of GAMT enzymatic
activity in brain and body fluids. The combined impact of Cr deficiency and GAA
accumulation might be responsible for the most severe phenotype.
Oral administration of Cr (0.35-2.0g/kg daily) is in part successful in treating AGAT
and GAMT deficiencies (Braissant, 2010). For GAMT deficiency patients, combined
arginine restriction and ornithine substitution helps decrease GAA concentration and improve
clinical outcome. Supplementation with high does of Cr, however, failed to normalize brain
Cr concentration. Even after treatment for months, total Cr concentrations in patients’ brains
stay significantly under normal level. Studies also show that early detection and
pre-symptomatic treatment might prevent the phenotypic expression of diseases in AGAT
and GAMT deficiencies (Braissant, 2010). On the other side, SLC6A8 deficiency can not be
treated by oral Cr supplement. In fact, no effective therapies are available for patients
suffering from SLC6A8 deficiency currently.
Although >90% of Cr is found in muscle tissue, the central nervous system (CNS)
seems to be the main organ affected in patients with Cr deficiency syndromes. A potential
explanation is that in muscle alternative phosphagen kinase systems could be developed
under the Cr deficiency conditions (Schlattner, 2003), whereas certain Cr functions in brain
can not be substituted by other systems. In recent years, evidences indicating that Cr may act
as neuromodulator, co-transmitter, or even true regulator of appetite and weight (Almeida et
9al., 2006; Cupello et al., 2008) were discovered. Studies in rat brain slices showed that Cr is
released from neurons in an action potential-dependent manner, requiring the presence of
Ca2+, inhibited by Na+-channel blocker tetrodotoxin, and enhanced by K+-channels blockade
4-aminopyridine (4-AP) (Almeida et al., 2006). Furthermore, Cr and GAA were reported to
act on post-synaptic GABAA receptors as a partial agonist (Cupello et al., 2008; De Deyn et
al., 1991; Neu et al., 2002). The supporting evidence also included the expression of
transport SLC6A8 in rat brain synaptosomes, which may suggest a Cr recapture mechanism
in axon terminal membrane (Peral et al., 2010).
Besides the inborn Cr deficiency syndromes because of gene mutation of key enzymes
and transporter in Cr metabolism, the secondary Cr deficiency in brain cells can be caused by
other CNS pathologies, including hyperammonemia, stroke and gyrate atrophy of the choroid
and retina (Beard and Braissant, 2010).
Hyperammonemia, which is usually caused by liver failure in adults, can lead to
irreversible damage to brain. Studies show that pathogenic mechanisms of hyperammonemia
may involve alterations in cerebral energy metabolism, neurotransmitter systems, nitric oxide
synthesis, and several amino acid metabolism pathways (Cagnon and Braissant, 2007).
Especially, excess of ammonium (NH4+) provokes a secondary Cr deficiency by inhibiting
AGAT, GAMT, and SLC6A8 gene expression and activity (Braissant, 2010). Data from
Braissant’s group also show co-treatment with Cr exhibits protective effects on some
pathological syndromes of hyperammonemia, especially axonal growth impairment.
10
Stroke is the second leading cause of human death worldwide. It is caused by blockage
(ischemic stroke) or leakage (hemorrhagic stroke) of brain blood, that results in insufficient
oxygen and glucose supply, leading to rapid loss of brain function (Feigin, 2005). Under the
circumstances of stroke, PCr is depleted rapidly to regenerate ATP. Also significantly lower
Cr concentrations were observed both in ischemic animal models and patients (Gideon et al.,
1992; Lei et al., 2009; Mathews et al., 1995). This lower Cr level is believed to contribute to
the failure of brain energy homeostasis and eventually induce neuronal death.
Gyrate atrophy of the choroid and retina is an inborn error of metabolism that is caused
by a mutation of ornithine δ-aminotransferase (OAT) gene (Valle et al., 1981). OAT
deficiency can increase concentration of plasma ornithine to 0.65-1.35 mM, which is 10-20
fold of normal level. Accumulated ornithine inhibits AGAT activity (Ki for ornithine is 0.25
mM) and results in lower concentration of GAA which is the precursor for Cr biosynthesis
(Valayannopoulos et al., 2009). Gyrate atrophy patients often suffer from a progressive loss
of vision, with total blindness usually occurring between the ages of 40 and 60. Gyrate
atrophy usually does not affect intelligence; however, unspecific neurological impairment
and premature degenerative changes may be observed in gyrate atrophy patients
(Nanto-Salonen et al., 1999. Some researchers believe that neurological impairment in gyrate
atrophy may be related to the secondary Cr deficiency in the CNS ( Valayannopoulos et al.,
2009).
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V. Creatine Supplement
Cr is one of the most common dietary supplements for athletes and bodybuilders. At
least three beneficial effects of Cr supplementation were observed in healthy people:
increasing muscle mass, enhancing performance in high-intensity short-duration exercise and
regulating carbohydrate metabolism (Branch, 2003).
Creatine supplementation was reported to increase muscle mass in an experiment
conducted by Francaux and Poortmans (1999). The daily supplement of 21 g creatine
monohydrate increased body mass by 2 kg on average compared with placebo group during 9
weeks strength-training program. In another double-blind experiment by Volek et al. (1999),
Cr supplement subjects showed significantly greater increases in Type I (35% vs 11%), IIA
(36% vs 15%), and IIAB (35% vs 6%) muscle fiber cross-sectional areas besides higher body
mass, compared with placebo subjects. Willoughby and Rosene (2003) investigated the
effects of oral creatine intake with resistance training on myogenic regulatory factor
expression and found significant increase of myogenin and MRF-4 at both mRNA and
protein concentrations. Simultaneous exercise, however, seems crucial for Cr supplement
benefits. Ferreira et al., (2005) reported that in the rat model Cr supplement alone did not
increase lean body mass, whereas Cr supplement in combination with exercise had larger
effects on lean body mass than exercise alone. In the study of Louis et al.(2003), who used
isotopic [1-(13)C] leucine to study human muscle protein turnover, no effect of Cr
supplementation was observed for subjects who did not exercise. Therefore, some researchers
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argued that increase in muscle mass with creatine supplementation must be associated with
increased physical activity.
The Cr/PCr/CK system functions as a shuttle of high-energy phosphate and therefore
enhances the ability to rapidly replenishing ATP during strenuous exercise. There is much
evidence supporting enhanced performance by Cr supplementation in short-duration,
high-density sports. A meta-analysis of 96 studies about Cr supplement by Branch (2003)
summarized that Cr supplement improved performance on high-intensity exercise of short
duration (< 30 s) but did not show significant effects on exercises lasting longer than 150
seconds. A study conducted by Vandenberghe et al. (1996) found that the ergogenic effect of
Cr could be completely eliminated by caffeine intake. Therefore, attention needs to be paid
because both Cr and caffeine are available in some common supplements. Cr is widely
consumed by athletes. One of most popular supplement schedules is a 5-6 day loading period
of 20 g per day, and sometimes followed by a maintaining period of 2-5 g per day.
Cr supplement also has been reported to affect muscle carbohydrate metabolism.
Glycogen content increases simultaneously with Cr content in muscle during the loading
period of 20 g Cr per day (Derave et al., 2003). Data about skeletal muscle-specific glucose
transporter GLUT-4 mRNA and protein concentrations, however, were not consistent among
different human experiments. Van Loon et al. (2004) reported no change in GLUT-4 mRNA
or protein level during Cr supplement of 6 weeks, whereas in a similarly scheduled study
(also 20 g Cr per day for 6 weeks) by Derave et al. (2003) GLUT-4 expression is increased
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by Cr supplementation. A rat study by Ju et al. (2005) found increased expression of GLUT4
and its transcription factor myocyte enhancer factor 2 isoforms by Cr supplementation. The
mechanism about how Cr affects muscle metabolism is not well understood yet. But, one
hypothesis involves the Cr/PCr ratio, which is increased by Cr supplementation. Cr/PCr ratio
was proved to modulate AMP kinase activity, which is one of key regulators of muscle
metabolism (Ponticos et al., 1998).
VI. Neuroprotective effects of creatine
The brain represents only 2% of body weight but consumes up to 20% of the energy
intake. Given the critical roles of Cr in cellular energy metabolism, the therapeutic potential
of Cr for neurological diseases has been studied extensively in both animal/cellular models
and human clinical trials. In these studies, Cr supplementation shows potential therapeutic
values for targeting cellular energy impairment in neurodegenerative diseases (Adhihetty and
Beal, 2008). In summary, the literature suggests that Cr supplementation exerts
neuroprotective effects on Parkinson’s disease (PD) and Huntington’s disease (HD) but
seems less effective in Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS)
(Adhihetty and Beal, 2008). Cr also may be used to modulate the neurological symptoms in
stroke or hyperammonemia that cause secondary Cr deficiency during disease process
(Braissant, 2010).
Parkinson’s disease (PD) is a neurodegenerative disease caused by death of
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dopaminergic neuron located in the substantia nigra in the midbrain. Early symptoms are
movement-related, including shaking, rigidity, slowness, and abnormality in gait. Cognitive
and behavioral problem may develop in later stages (Jankovic, 2008). Impaired activity of
complex I in the mitochondrial electron transport chain has been proved as the key factor in
the disease process. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was found to
inhibit complex I activity and lead to PD-like syndromes in human and animal models
(Langston et al., 1983). It is commonly used in PD studies. Matthews’ group (1999) showed
that oral Cr supplementation resulted in significant protection against MPTP-induced
dopamine depletion and neuron death in mice. In a randomized, double-blind phase II clinical
trial, 4 g/d of Cr was administrated for a period of two years to 60 PD patients. The results
indicated  that long-term Cr supplementation was safe and thus was recommended for Phase
III clinical trials (Bender et al., 2006; Bender et al., 2008). According to Adhihetty and
Beal’s report in 2008, a double-blind, placebo-controlled, phase III clinical study involving
1,720 early-stage PD patients and lasting for 5-7 years was underway. This study is one of
the largest PD clinical trials to date. The final report from this study, however, is not
available yet.
Huntington’s disease (HD) is caused by an autosomal dominant mutation on huntingtin
gene that results in an abnormal polyglutamine expansion in the huntingtin protein. Normal
huntingtin protein is expressed extensively in vertebrates with unclear function. Mutant
huntingtin protein is reported to be toxic to neural cell by inducing transcriptional
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dysregulation, oxidative injury, proapoptotic signaling, inflammatory reaction, and
mitochondria dysfuntion (Beal and Ferrante, 2004). Cr supplementation in transgenic mice
models of HD was shown to improve motor performance, increase life span, and delay the
formation of mutant huntingtin aggregates (Andreassen et al., 2001; Dedeoglu et al., 2003;
Ferrante et al., 2000). A 16-week, randomized, double-blind, placebo-controlled phase II
clinical trial was conducted by (Hersch et al., 2006) to test the safety, tolerability, and
efficacy of 8 g/day Cr in 64 subjects with HD. This study reported that Cr dosage was well
tolerable and Cr treatment successfully suppressed serum 8-hydroxy-2'-deoxyguanosine, an
indicator of oxidative injury to DNA. Because of the neuroproctective effects illustrated in
both transgenic mice models and phase II clinical trials, a large scale phase III clinical trial
has been approved and is currently ongoing.
Alzheimer’s disease (AD) is one of the most common forms of dementia, which is
characterized by loss of neurons in cerebral cortex and specific subcortical regions (Wenk,
2003). Late stage of AD shows inactive CK and Cr deposition, which implies Cr
supplementation at late stage may not exert any improvement (Adhihetty and Beal, 2008).
The benefits, however, remain possible with Cr supplementation in earlier stage.
Amyotrophic lateral sclerosis (ALS) is a progressive, usually fatal, neurodegenerative
disease, caused by loss of motor neurons in CNS. Creatine administration in an ALS animal
model (G93A mice) improved motor performance, protected against neurons loss, and
decreased oxidative damage (Klivenyi et al., 1999). No beneficial effects of Cr
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supplementation, however, were observed in two independent clinical trials with ALS
patients (Groeneveld et al., 2003; Shefner et al., 2004). Further studies are needed to explain
the differences in the efficacy of Cr treatment between ALS mice model and patients.
One common characteristic of neurological diseases is neuron death or loss of function
in distinct areas of the brain. Mitochondria are not only the “powerhouse of the cell” but also
regulate cell apoptosis because they produce the majority of damaging reactive oxygen
species (ROS) by electron transport chain and can induce cell death by releasing
pro-apoptotic factors to the cytosol (McBride et al., 2006). A continuum between inner and
outer mitochondrial membrane, called mitochondrial permeability transition pores (mtPTP),
is required for the release of pro-apoptotic proteins. Substantial evidence indicates that
mitochondrial dysfunction is involved in pathogenesis of numerous neurodegenerative
diseases, including HD (Browne et al., 1997), PD(Thomas and Beal, 2007), ALS (Beal, 2000)
and AD (Ferreira et al., 2010). Although the mechanisms differ slightly in specific diseases,
Cr supplementation has been proposed and/or proven to improve the overall bioenergetics
and mitochondria function. Detailed information about the mechanism is shown in Figure 4.
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Figure 4. During the pathological process of neurodegeneration, mitochondrial impairment
causes accumulation of ROS, which can change the octameric conformation of mitochondrial
creatine kinase (MtCK) to its dimeric form. Octameric MtCK can suppress mtPTP opening
by interacting with both the outer membrane component voltage-dependent anion channel
(VDAC) and the inner membrane component adenine nucleotide translocase (ANT) whereas
the inactivated dimeric form of MtCK can’t. The shift of the octameric form to the dimeric
form has also been shown to affect Ca2+ homeostasis, which is another factor contributing to
the opening of mitochondrial permeability transition pores (mtPTP). Cr supplementation
stabilizes the octameric form of MtCK, and therefore decrease mitochondrial apoptotic
18
susceptibility (Adopted from Adhihetty and Beal, 2008; Beard and Braissant, 2010).
Carnosine and anserine
I. Structure information
L-Carnosine (ß-alanyl-L-histidine) is a dipeptide composed of ß-alanine and
L-histidine, which is highly concentrated in muscle and brain tissues of mammals. Carnosine
performs multiple biological functions including pH buffering, anti-oxidation, anti-glycation,
ant-aging, and chelation of divalent metal cations. Anserine (ß-alanyl-N-methylhistidine) is
an N-methylated analogue of carnosine found mainly in fish and birds. The structures of
carnosine and anserine are shown in Figure 5. Anserine has similar properties with carnosine
in many aspects but is mainly found in non-mammalian species. In this review, the
discussion is focused on carnosine.
Figure 5.  Structures of carnosine, anserine, L-α-alanine, and β-alanine.
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II. Carnosine metabolism
As a dipeptide, carnosine has a relatively simple synthetic pathway compared with
creatine. Carnosine is synthesized by carnosine synthase from its constituent amino acids
ß-alanine and L-histidine. L-Histidine is an essential amino acid that can only be obtained
from the diets, whereas ß-alanine is a non-essential amino acid and the rate-limiting
precursor. In some cases, ß-alanine supplementation is used to increase muscle carnosine
concentration. Differing from L-α-alanine that is used in major protein synthesis, the amino
group of ß-alanine is located on ß carbon rather than α carbon. The structural difference
between L-α-alanine and ß-alanine is also shown in Figure 5. ß-Alanine can be produced via
the following three pathways: the decarboxylation of aspartate by gut microbes, the
interchangeable reaction of pyruvate to L-α-alanine, and the deamination and carboxylation
of the pyrimidine uracil (Tiedje et al., 2010). Recently, carnosine synthase was identified as
the ATP-grasp domain-containing protein 1(ATP-GD 1) (Drozak et al., 2010). The structure
and function details of this enzyme, however, remain unclear.
Carnosine hydrolysis is catalyzed by carnosinase. In human, two forms of carnosinase
were discovered: serum carnosinase (CN1) and tissue carnosinase (CN2). CN1 was identified
as a homodimeric dipeptidase with narrow substrate specificity whereas CN2 could exert
dipeptidase activity on a wider range of substrates. Because of the existence of CN1 in
human serum, the blood carnosine concentration is very low. On the contrary, rodents do not
have carnosinase in serum, and their blood does contain much higher concentrations of
20
carnosine (Teufel et al., 2003).
Regulation of carnosine homeostasis is understood poorly. Nagai et al. (2003)
suggested that muscle contraction or exercise influenced all aspects of carnosine metabolism,
including synthesis, degradation, and transportation. According to the homology modeling by
Vistoli et al. (2006), the activity of serum carnosinase is stimulated by citrate. Schulz et al.
(1989), on the other hand, observed that cAMP inhibited the activity of carnosine synthase.
These studies suggest that carnosine concentration is under metabolic regulation. Further
studies, however, are required to reveal detailed mechanisms.
III. Physiological functions of carnosine
Carnosine performs multiple biological functions, including pH buffering, metal ion
chelation, and anti-glycation. Carnosine exerts beneficial health effects, such as antioxidation,
antiaging, and preventing hangovers (Hipkiss, 2009a).
The pKa of carnosine is 6.8, which fall into the physiological pH range (6.5-7.1) of
myocytes. It can dynamically accept protons produced during muscle contraction. Therefore,
the pH buffering ability of carnosine may explain its abundance in muscle tissue and also the
protective role in ischaemia acidosis.
Carnosine can chelate divalent metal ions with its imidazole ring. It is considered as a
protective agent against heavy metal-induced toxicity (Trombley et al., 2000). The chelation
property with ferrous ions and other transition metals also contributes to the antioxidative
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capacity. It is well known that transition metals promote the production of ROS  through the
Fenton reaction (Bondy et al., 1998).
Glycation is uncontrolled reaction of sugar aldehyde with amino groups of protein. It
causes protein cross-linking and other harmful advanced glycation end products that are
involved in the process of aging. In vitro studies showed that carnosine could react with
multiple glycation reagents and the product was non-mutagenic. Therefore, carnosine could
inhibit glycation and prevent protein cross-linking (Hipkiss et al., 1995). After ethanol
consumption, serum acetaldehyde concentration increases to cause “hangover”. Carnosine
could react with acetaldehyde and be considered as an effective way to prevent “hangovers”
and other alcohol-induced damages (Hipkiss et al., 1998). By decreasing the production of
ROS and deleterious aldehydes, carnosine was proposed to suppress the process of aging at
both cellular and whole organism levels (Hipkiss, 2009a).
IV. Carnosine supplement
Given the favorable physiological properties, such as pH buffering, anti-oxidation, and
anti-glycation, carnosine has been proposed as a potential therapeutical adjuvant in various
diseases, including cataract, diabetic complications, ischemia and Alzheimer’s disease
(Hipkiss, 2009b; Janssen et al., 2005; Kawahara et al., 2007; Quinn et al., 1992).
Because of the existence of serum carnosinase in human, the efficacy of carnosine
supplementation is of concern. In the experiment by Gardner et al. (1991), administration of
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4 g of carnosine increased plasma carnosine concentration up to 180 mg/ml within 0.5 hour
after intake. The plasma carnosine, however, returned to undetectable level after 2 hours. In
another study by Park et al. (2005), the absorption kinetics were studied by consuming
cooked ground beef containing 248 mg of carnosine. Carnosine was detected in plasma 15
min after beef consumption, continued to increase up to 32.7 mg/L 2.5 hours after
consumption, and then decreased to undetectable level at 5.5 hours. The studies suggest that
dietary carnosine is absorbed intact and causes at least temporarily raised serum carnosine
concentration. Antonini et al. (2002) showed that serum total antioxidant activity was
increased by 11% 1 hour after intake of 450 mg of carnosine. This study indicates that,
despite the presence of serum carnosinase, dietary carnosine supplement still has the
potential to exert its health benefits on tissues.
Carnosine analogues were designed to resist carnosinase attack. N-acetyl-carnosine is
one example. After entering cells, of N-acetyl-carnosine undergoes removal of its acetyl
group and is transformed into carnosine. In fact, the ophthalmic drugs with
N-acetyl-carnosine formula are currently available for patients with age-related cataracts
(Babizhayev, 2004).
The ideal daily supplement dose for carnosine has not been decided yet. Currently, the
commercial capsule for carnosine supplement contains 200-500 mg of carnosine. Carnosine
naturally exists only in animal tissues, and therefore vegetarian diets may be deficient in
carnosine. Carnosine concentration varies according to animal species and tissues (Hipkiss,
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2009a). Muscle type, gender and age also were reported to affect carnosine content in tissue
of humans and rodents. In humans, fast twitch muscle fibers have significantly higher
amount of carnosine than do slow twitch fibers (Derave et al., 2010). Penafiel et al. (2004)
observed the marked sexual dimorphism of carnosine and anserine in skeletal muscles of
CD1 mice. They found that male mice have 3-4 fold higher carnosine contents than do
females, and testosterone administration could increase female muscle carnosine content to
a similar level of males. In humans, the same trend but smaller gender differences were
observed. Mannion et al. (1992) studied carnosine concentrations in the lateral portion of
the quadriceps femoris muscle of 50 healthy human subjects and reported that on average
men had 20-25% higher carnosine concentration than did women. Besides, muscle
carnosine content remarkably declines with age in both rodents and humans (Johnson and
Hammer, 1992; Tallon et al., 2007).
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Abstract
The objective of this study was to investigate the variation of creatine, creatinine,
carnosine, and anserine contents in longissimus muscle of Angus cattle and their correlations
with carcass and palatability traits. Longissimus muscle samples were collected from 2,342
Angus cattle fed in Iowa (n=1,114), Texas (n=455), Colorado (n=391), and California
(n=382). Creatine, creatinine, carnosine, and anserine were extracted from beef and
quantified by high-performance liquid chromatography. The concentrations of these
compounds then were correlated with carcass and palatability traits including hot carcass
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weight (HCW), kidney pelvic heart fat percentage (KPH), ribeye area, fat thickness, marbling
score, calculated yield grade, sensory panel scores, Warner Bratzler shear force (WBSF), and
thiobarbituric acid reactive substances (TBARS). Statistical analysis showed that the gender
of cattle significantly (P < 0.05) affected the concentrations of creatine, creatinine, carnosine,
and anserine. Bulls contained greater creatine content than did steers (P < 0.05) but produced
lower amount of carnosine than did heifers (P < 0.05). Significant variation from feeding
location was also observed. The correlations with carcass quality and sensory scores were
significant but weak, which suggested that beef quality, especially tenderness, juiciness, and
flavor, would not be strongly affected by selecting for higher creatine and carnosine contents.
Keywords: beef, creatine, creatinine, carnosine, anserine, palatability, carcass,
correlations
Introduction
Creatine and carnosine have been considered as valuable nutraceuticals in meat
products for a long time. Creatine as energy buffer plays an important role in cellular
metabolism and shows protective effects in neurodegenerative diseases such as Parkinson’s
disease and Huntington’s disease (Adhihetty and Beal, 2008; Beard and Braissant, 2010;
Bender et al., 2006; Dedeoglu et al., 2003; Hipkiss, 2009b; Wyss and Kaddurah-Daouk,
2000). Carnosine has multiple physiological functions associated with anti-oxidation and
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anti-aging (Antonini et al., 2002; Derave et al., 2010; Hipkiss, 2009b; Janssen et al., 2005;
Trombley et al., 2000). Creatinine is the spontaneously formed cyclic derivative of creatine.
Anserine is an N-methylated analogue of carnosine found mainly in fish and birds. Because
creatine and carnosine exist naturally only in animal muscle and brain tissues, meat is an
important source of dietary creatine and carnosine. Few studies, however, have focused on
creatine and carnosine concentrations in beef and the factors influencing their concentrations.
Health concerns have arisen about beef intake mainly because of its high amount of
saturated fatty acids. To improve the nutritional value of beef, creatine and carnosine, as
beneficial nutraceuticals, could be potential targets for selection. In the meantime, beef
producers and consumers highly value meat quality and palatability traits, especially
tenderness. Ideally, producers would like to select beef for optimal health values without
compromising production efficiency and consumer satisfaction. To fulfill this goal, the
relationship among beef creatine and carnosine contents with meat quality and sensory
characteristics must be understood first. Therefore, the objective of the present study was to
investigate (1) the variation of creatine and carnosine along with creatinine and anserine
contents in longissimus muscle of Angus cattle and (2) their correlations with carcass and
palatability traits. The potential influences of gender and feeding location also were evaluated
in our study.
Materials and Methods
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Animal Resources and Sample Collection
Angus cattle (n=2,342) in this study had related genetic background, but were raised in
different feedlots in Iowa (n=1,114), Texas (n=455), Colorado (n=391), and California
(n=382). Cattle from Iowa included three gender types: bulls (n=558), steers (n=316), and
heifers (n=240). Both steers (n=192) and heifers (n=199) were available in Colorado. Cattle
from Texas and California were all steers. Cattle were harvested and processed by
contemporary groups (n=33) on the basis of feeding location, gender, birth season, and
harvest date.
Carcass and Palatability Data Collection
Carcass data, including hot carcass weight (HCW), kidney pelvic heart fat percentage
(KPH), ribeye area, fat thickness, marbling score, and calculated yield grade were obtained
by trained personnel. Rib sections were collected from each carcass at commercial facilities
at Iowa, Texas, Colorado, and California. More detailed information for animal management,
sample collection, and processing can be found in Garmyn et al. (2011).
Assessment of palatability traits also was described in Garmyn et al. (2011).. In
summary, frozen steaks were thawed at 4°C for 24 h and then cooked to a final internal
temperature of 68 °C. Six cores of 1.27 cm diameter were removed from each cooked steak
for Warner Bratzler shear force (WBSF) measurement. The mean value of six measurements
was used in further analysis of each sample. Trained sensory panel measured each sample on
initial tenderness, overall tenderness, initial juiciness, sustained juiciness, and amount of
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connective tissue with an 8-point scale (higher value for more favorable quality). Beef flavor,
painty/fishy flavor, and livery/metallic flavor were evaluated with a 3-point scale (1=not
detectable, 2=slightly detectable, and 3=strong). Thiobarbituric acid reactive substances
(TBARS) were used to evaluate lipid oxidation, and the results were expressed as mg of
malonaldehyde per kg of sample.
Creatine, Creatinine, Carnosine, and Anserine Analysis
Creatine, creatinine, carnosine, and anserine were extracted from beef and analyzed by
high-performance liquid chromatography by using methods adapted from Mora et al. (2007).
Briefly, 6 mL of 0.01 N HCl was added to 2 g of ground, homogenized beef and vortexed for
15 sec. These samples were placed on an orbital shaker for 15 min and centrifuged for 20
min at 12,000 × g and 4° C. The supernatant was filtered through glass wool and 250 µL
were deproteinized by mixing with 750 µL of acetonitrile. These samples were held at 4° C
for 20 min before centrifugation at 10,000 × g for 10 min.
Chromatography was performed by using a Hewlett-Packard 1050 HPLC equipped
with a quaternary pump, autosampler, and variable wavelength detector. An injection volume
of 20 µL of deproteinized supernatant was separated on an Atlantis HILIC silica column (4.6
× 150 mm, 3 µm; Waters Corporation, Milford MD). Solvent A consisted of 0.65 mM
ammonium acetate in water/acetonitrile (25:75, v: v) with pH at 5.5. Solvent B consisted of
4.55 mM ammonium acetate in water/acetonitrile (70:30, v: v) with the same pH. The solvent
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gradient was linear from 0% solvent B to 100% solvent B in 13 min and a return to 0%
solvent B in 2 min followed by re-equilibration at initial conditions for 5 min. Solvent flow
rate was set at 1.4 mL/min. The variable wavelength detector was initially set at 236 nm and
was changed to 214 nm after 4 min. Sample peak areas were correlated to standard curves of
creatinine, creatine, carnosine, and anserine for quantification.
Statistical Analysis
Statistical analyses were performed with SAS (SAS Inst. Inc., Cary, NC). The average,
minimal, and maximal values for each trait were calculated by using PROC UNIVARIATE.
Because not all genders were present or equally represented at each feeding location
(e.g., Iowa was the only location from which samples included all three gender types,
whereas heifer and bull samples were missing at California and Texas), gender effects were
evaluated on samples from Iowa by a mixed model with gender and birth season as fixed
effects, dam and sire as random effects, and harvest age as covariate. Similarly, only steer
samples were available from four locations. A mixed model with feeding location as fixed
effect, dam and sire as random effects was applied to evaluate the effect of feeding location
using only steer samples. Harvest age was not included in this model because it was only
recorded in the production system from Iowa. Birth season was dropped because of a lack of
degrees of freedom. The P-value was obtained from analysis of variance and considered to be
significant if it was less than 0.05.
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The simple correlation coefficients were calculated by using PROC CORR of SAS.
Partial correlation coefficients were obtained from MANOVA/PRINTE option in PROC
GLM. The Spearman correlation coefficients were reported for traits with ranked scores,
including marbling scores and sensory scores. For other traits, Pearson correlation
coefficients were used. The correlation was considered significant when the P-value was less
than 0.05.
Results and Discussion
Variation in beef creatine, creatinine, carnosine, and anserine concentrations
The simple statistics of beef creatine, creatinine, carnosine, and anserine concentrations
in longissimus muscle of Angus cattle are shown in Table 1. The concentration of creatine
ranged from 2.58 to 6.86 mg/g of ground beef, with an average at 5.26 ± 0.01 mg/g. We
observed highest carnosine content at 5.72 mg/g and lowest content at 2.28 mg/g, with an
average at 3.72 ± 0.01 mg/g of beef. Our data fell into similar ranges reported by Purchas et
al. (2005) in the study of Angus-cross heifers raised in United States and New Zealand. They,
however, reported a lower average creatine concentration (3.82 mg/g) but a higher average
carnosine concentration (4.27 mg/g).
Beef is a good source of dietary creatine and carnosine, when compared with other
meat products, especially red meat. In the study of Pais et at. (1999) who investigated
creatine contents in beef, chicken breast, chicken thigh, turkey breast, and fish, the highest
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creatine concentration (6.33 mg/g) was observed in beef top round steak. Hipkiss (2009) also
reported higher carnosine concentration in beef than in pork or lamb. According to our study,
the amount of creatine present in a typical serving (100 g) of beef is generally lower than that
recommended for supplementation (e.g., a typical creatine supplement protocol asks for 5 g
of creatine per day for four days and then a maintenance dose of 2 g per day) (Wyss and
Kaddurah-Daouk, 2000). Although the ideal daily supplement dose for carnosine has not
been decided yet; the commercial capsule usually contains 200-500 mg of carnosine, which
is similar with the amount in one serving of beef (100 g).
Effects of gender and feeding location on beef creatine, creatinine, carnosine, and
anserine concentrations
The results of gender effect based on samples from Iowa are shown in Table 2. The
gender of cattle significantly affected the concentrations of creatine, creatinine, carnosine,
and anserine in longissimus muscle. Bulls contained greater creatine content than did steers
(P < 0.05), which could be attributed to the effects of sex hormones on endogenous creatine
synthesis (Krisko and Walker, 1966; Wyss and Kaddurah-Daouk, 2000). In contrast, heifers
had 9.6% higher amounts of carnosine than did bulls (P < 0.05), which indicated an opposite
gender effect with rodents and humans (Mannion et al., 1992; Penafiel et al., 2004). Their
studies showed males tended to have greater muscle carnosine content than do females in
both mice and humans. We also observed that heifers had significantly higher (P < 0.05)
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creatinine concentration than did steers and bulls, whereas steers had higher anserine content
than did bulls and heifers (P < 0.05).
The same gender effect model was applied to carcass and palatability traits. As shown
in Table 3, gender was a significant source of variation on each reported carcass trait. Bulls
produced the heaviest hot carcass weight and the largest ribeye area (P < 0.0001), which was
followed by steers; and heifers received the lowest scores on both traits. In contrast, bulls
received significantly lower marbling scores than did steers (P < 0.001). These results were
expected because testosterone promotes rapid lean muscle growth but decreases fat
deposition (Fritsche and Steinhart, 1998; Guillemin et al., 2009; Schreurs et al., 2008). They
were also in agreement with previous studies of Choat et al. (2006), which suggested that
steers had higher rate of gain than did heifers across a feeding period. Our study, however,
found that steers had highest yield grade, KPH fat percentage, and 12th rib fat thickness (P <
0.05), which were not observed in the study of Choat et al. (2006).
Table 4 shows gender effect on beef palatability traits, including both trained sensory
panel scores on tenderness, connective tissue amount, juiciness and flavor, and other
measurements, including Warner-Bratzler Shear Force (WBSF) and thiobarbituric acid
reactive substances (TBARS). Steers received more favorable ratings from the sensory panel
on initial tenderness, overall tenderness, and connective tissue amount compared with bulls.
Although similar gender effects on beef tenderness were reported in other studies (Peachey,
2002; Purchas et al., 2002) and could be explained by the positive association between
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intramuscular fat content and tenderness (Wood J.D., 2008), no significant difference
between steers and bulls on WBSF (P > 0.05) were observed. On the other hand, heifer was
reported to have the lowest WBSF score (P < 0.05) and the highest TBARS value (P < 0.05)
in this study. Steers received significantly higher scores on beef flavor and significantly
lower painty/fishy flavor than other two groups. No significant differences among groups
were observed on sensory scores regarding initial juiciness, sustained juiciness, and
livery/metallic flavor in our study (P > 0.05).
Effects of feeding location on beef creatine, creatinine, carnosine, and anserine are
reported in Table 5 based on data of steers. No significant differences among four feeding
locations were found on creatinine (P > 0.05). In contrast, feeding location is a significant
source of variation for creatine, carnosine, and anserine. Steers fed in California had
significantly lower amount of creatine than did those fed in both Texas and Iowa. Steers fed
in Colorado had the highest carnosine concentration, followed by steers fed in Iowa and
California, whereas steers fed in Texas had the lowest carnosine concentration in longissimus
muscle. With limited information about harvest age for cattle from Colorado and Texas, we
could not rule out the possibility that the difference was actually attributed to cattle age. It is
well accepted that skeletal muscle carnosine concentration declines with age in humans and
rodents (Johnson and Hammer, 1992; Tallon et al., 2007). In the study of Purchas R.W.
(2005), who compared the production systems of US and New Zealand, beef samples from
two countries showed significant difference on both creatine and carnosine contents. The
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genetic differences between US and New Zealand cattle in their study, however, need to be
considered to interpret results properly.
Correlations among beef creatine, creatinine, carnosine, and anserine with carcass and
palatability traits
The simple correlation coefficients with carcass and palatability traits are present in
Table 6 and Table 7, respectively. Creatine concentration was correlated positively with
ribeye area (r=0.085), TBARS (r=0.099), and connective tissue amount (r=0.096) but
negatively with fat thickness (r=-0.133), marbling (r=-0.235), calculated yield grade
(r=-0.127), juiciness (r=-0.135 for initial juiciness and r=-0.102 for sustained juiciness), and
flavor (r=-0.066 for beef flavor and r=-0.134 for painty/fishy flavor). Positive correlations
were found among creatinine with hot carcass weight (r=0.085), fat thickness (r=0.284),
marbling (r=0.082), calculated yield grade (r=0.271), tenderness (r=0.095 for initial
tenderness and r=0.056 for overall tenderness), juiciness (r=0.191 for initial juiciness and
r=0.133 for sustained juiciness), and flavor (r=0.149 for beef flavor, r=0.124 for painty/fishy
flavor and r=0.066 for livery/metallic flavor). We observed weak negative correlations
between creatinine with KPH fat percentage (r=-0.091) and ribeye area (r=-0.083) but
relatively strong negative correlation with TBARS (r=-0.419). Similarly, carnosine was
correlated negatively with fat thickness (r=-0.239), marbling (r=-0.047), calculated yield
grade (r=-0.161), TBARS (r=-0.060), tenderness (r=-0.070 for initial tenderness and r=-0.098
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for overall tenderness), and connective tissue amount (r=-0.107) but positively correlated
with KPH fat percentage and flavor (r=0.102 for beef flavor and r=0.069 for livery/metallic
flavor). As for anserine, the positive correlations with KPH fat percentage (r=0.162), ribeye
area (r=0.043), TBARS (r=0.107), overall tenderness (r=0.060), connective tissue amount
(r=0.064), and beef flavor (r=0.062) and the negative correlations with WBSF (r=-0.122) and
painty/fishy flavor (r=-0.172) were found. The large sample size of this study (n=2,342)
allowed us to detect weak correlations. Although all these correlations were reported at
statistically significant level (P<0.05), we should notice that the absolute values of
correlation coefficients were very small (less than 0.25) in most instances.
Partial correlation coefficients also were calculated to examine the relationship
between nutraceuticals and meat quality traits after accounting for group variation caused
by gender, feeding location, and birth seasons. Table 8 and Table 9 report partial correlation
coefficients among traits. After removing group differences, creatine was only significantly
correlated with ribeye area (r=0.061), marbling (r=-0.129) and calculated yield grade
(r=-0.068). Creatinine showed no significant correlation with TBARS, fat thickness, and
calculated yield grade (P>0.05), which indicated that the previously reported moderate
simple correlations might over-estimate the relationship among them. Weak partial
correlations, however, were found among creatinine and ribeye area (r=0.078), tenderness
(r=-0.053 for initial tenderness and r=-0.052 for overall tenderness), and flavor (r=0.074 for
beef flavor and r=-0.063 for painty/fishy flavor). Similarly, carnosine was correlated weakly
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with hot carcass weight (r=-0.047), KPH fat percentage (r=0.049), marbling scores
(r=-0.072), WBSF (r=-0.131), tenderness (r=-0.119 for initial tenderness and r=-0.100 for
overall tenderness), connective tissue amount (r=-0.065), juiciness (r=-0.077 for initial
juiciness and r=-0.067 for sustained juiciness), and painty/fishy flavor (r=-0.102). As for
anserine, the significant partial correlation was observed only with hot carcass weight
(r=-0.076). Compared with simple correlations, even smaller absolute values were observed
for partial correlation coefficients.
Because creatine, creatinine, carnosine, and anserine were distributed only in muscle
tissue (Hipkiss, 2009a; Wyss and Kaddurah-Daouk, 2000), the negative associations with
traits related to intramuscular fat content, such as marbling and tenderness, were expected.
Our data, however, showed the correlations among them to be very weak, especially after
removing the group differences (partial correlation coefficients). At physiological
concentrations in muscle, carnosine can scavenge reactive oxygen species and have
anti-oxidant effects (Hipkiss, 2009a). Therefore, it is believed that carnosine can reduce
products of lipid peroxidation (TBARS) (Derave et al., 2010). Our study did not show
strong negative correlation between carnosine content and TBARS (r=-0.060 for simple
correlation coefficient (P<0.05) and r=-0.031 for partial correlation coefficient (P>0.05)). It
should be noticed that samples in this study showed small TBARS values (with the average
at 0.19 ± 0.01 mg/kg) compared with the threshold value of acceptability at 2 mg/kg, which
indicated little lipid oxidation opportunity was allowed during sample collection and
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processing (Garmyn et al., 2011). The low TBARS values might explain the weak
correlations between carnosine and TBARS in this study.
Acceptance on meat quality by consumers should be considered fully during the
selection of meat with better health value. For instance, concerns are raised about leanness in
the pork industry because of the positive association between intramuscular fat content and
tenderness (Wood J.D., 1986; Wood J.D., 2008). The weak correlations among creatine and
carnosine with carcass and palatability traits observed in our study indicate that beef quality,
especially tenderness, juiciness, and flavor will not be strongly affected by selecting for
higher creatine and carnosine contents. Because few other studies directly calculated the
correlation coefficients among creatine, carnosine, and meat quality traits, it is difficult to
compare our results with other studies. The relationship between these nutraceuticals and
meat quality, however, can be inferred from the experiments in which creatine or carnosine
were used as dietary supplements. Dietary administration of creatine monohydrate was
reported to have influences on postmortem pH, water-holding capacity, and meat color but to
have little or no impacts on other pork quality parameters, especially on tenderness and
juiciness (Berg and Allee, 2001; O'Quinn et al., 2000; Stahl et al., 2001). Similar results were
observed on chicken with creatine supplement (Nissen and Young, 2006). In the study of
Derave et al. (2010), who investigated the influence of dietary supplement with carnosine on
meat quality of finishing pigs, carcass traits including carcass weight, yield grade,
longissimus muscle area, back fat thickness, shear force, and marbling score were not
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affected by the dose up to 100 mg carnosine per kg diet for 8 weeks. Despite the potential
difference among species, these results supported for the weak correlations observed in our
study.
Implication
Beef is good source of dietary creatine and carnosine when compared with vegetarian
diets or other red meat product. Beef creatine and carnosine contents are affected by gender
and feeding locations. The correlations, although weak, among creatine and carnosine
contents with carcass quality and beef palatability provide the possibility of optimal selection
of healthful beef without compromising production efficiency or consumer satisfaction.
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Tables
Table 1. Simple statistics for creatine, creatinine, carnosine, and anserine concentrations in
longissimus muscle of Angus cattle1
Item Mean Minimal Maximal
Creatine (mg/g) 5.26 2.58 6.86
Creatinine (mg/g) 0.207 0.034 0.553
Carnosine (mg/g) 3.72 2.28 5.72
Anserine (mg/g) 0.668 0.140 1.218
1Traits were expressed as mg per g wet tissue
Table 2. Effect of gender on creatine, creatinine, carnosine, and anserine concentrations in
longissimus muscle of Angus cattle1 from Iowa.
Item Bull Steer Heifer P
Creatine (mg/g) 5.30±0.03 a 5.12±0.02 b 5.22±0.06 a,b <0.0001
Creatinine (mg/g) 0.167±0.006 a 0.178±0.005 a 0.235±0.015 b  0.0018
Carnosine (mg/g) 3.76±0.05 a 3.77±0.05 a 4.12±0.10 b 0.0003
Anserine (mg/g) 0.68±0.01 a 0.71±0.01 b 0.65±0.03 a <0.0001
a,bMeans within a row lacking a common superscript differ (P<0.05).
1Traits, per gram wet tissue, are expressed as least squares means±SE.
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Table 3. Effect of gender on carcass traits of Angus cattle1 from Iowa.
Item Bull Steer Heifer P
Hot carcass weight, kg 352.46±2.50a 320.10±4.83b 268.94±5.98c  <0.0001
KPH fat2, % 2.25±0.03 a 2.30±0.02 a 1.96±0.07 b <0.0001
Ribeye area3, cm2 86.26±0.58a 78.65±0.52b 72.39±1.29c <0.0001
12th rib fat thickness4, cm 0.99±0.03a 1.09±0.04a 0.88±0.07b <0.0001
Marbling score5 5.41±0.07a 6.44±0.06c 5.91±0.16b <0.0001
Calculated yield grade6 2.61±0.04 b 2.84±0.03 a 2.36±0.09 c <0.0001
a,b,cMeans within a row lacking a common superscript differ (P<0.05).
1Traits are expressed as least squares means±SE.
2Estimated of percentage of kidney, pelvic, and heart fat, % of carcass weight.
3Longissimus dorsi cross sectional area at carcass split between the 12th and 13th ribs.
4Measured at 3/4 the lateral distance across the Longissimus dorsi from the spine at carcass split
between the 12th and 13th ribs.
53.0=traces; 4.0=slight; 5.0=small; 6.0=modest; 7.0=moderate; 8.0=slightly abundant; 9.0=moderately
abundant (based on USDA system).
6Yield grade= 2.5 + (6.35 × fat thickness, cm) + (0.2 × KPH %) + (.0017 ×hot carcass weight, kg) -
(2.06 × ribeye area, cm2)
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Table 4. Effect of gender on Warner-Bratzler Shear Force (WBSF), thiobarbituric acid reactive
substances (TBARS), and palatability traits of beef from Angus cattle1 fed in Iowa.
Item Bull Steer Heifer P
WBSF, kg 3.61±0.06 a 3.49±0.05 a 2.80±0.15 b <0.0001
TBARS2, mg/kg 0.126±0.005 a 0.143±0.004 b 0.187±0.008 c <0.0001
Initial tenderness3 5.38±0.10a 5.69±0.07b 5.73±0.15a,b 0.0004
Overall tenderness3 5.25±0.10a 5.69±0.07b 5.73±0.15 a,b <0.0001
Connective tissue4 5.32±0.10a 5.66±0.08b 5.76±0.15a,b <0.0001
Initial juiciness5 5.38±0.07 5.41±0.05 5.27±0.11 0.4002
Sustained juiciness5 5.06±0.07 5.10±0.05 4.83±0.10 0.0603
Beef flavor6 2.43±0.04 a 2.56±0.03 b 2.39±0.06 a <0.0001
Painty/fishy flavor6 1.19±0.03 a 1.11±0.02 b 1.25±0.05 a <0.0001
Livery/metallic flavor6 1.07±0.02 1.08±0.01 1.12±0.02 0.5129
a,bMeans within a row lacking a common superscript differ (P<0.05).
1Traits are expressed as least squares means±SE.
2Expressed as mg of malonaldehyde per kg of sample.
31=Extremely tough; 2=Very tough; 3=Moderately tough; 4=Slightly tough; 5=Slightly tender;
6=Moderately tender; 7=Very tender; 8=Extremely tender.
41=Abundant; 2=Moderately abundant; 3=Slightly abundant; 4=Moderate; 5=Slight; 6=Traces;
7=Practically none; 8=None.
51=Extremely dry; 2=Very dry; 3=Moderately dry; 4=Slightly dry; 5=Slightly juicy; 6=Moderately
juicy; 7=Very juicy; 8=Extremely juicy.
61=Not detectable; 2=Slightly detectable; 3=Strong.
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Table 5. Effect of feeding location on creatine, creatinine, carnosine, and anserine concentrations in
longissimus muscle of Angus steers1.
Item CA TX CO IA P
Creatine (mg/g) 5.56±0.04 a 5.03±0.04 b ------------ 5.15±0.04 b <0.0001
Creatinine (mg/g) 0.15±0.07 0.29±0.05 0.32±0.09 0.17±0.03  0.1972
Carnosine (mg/g) 3.53±0.03b 3.39±0.03 a 4.09±0.03 d 3.84±0.03 c <0.0001
Anserine (mg/g) 0.68±0.01 b,c 0.64±0.01 a,b 0.63±0.01 a 0.70±0.01 c  0.0017
a,bMeans within a row lacking a common superscript differ (P<0.05).
1Traits, per gram wet tissue, are expressed as least squares means±SE.
Table 6. The simple correlation coefficients(r) 1 between creatine, creatinine, carnosine, and anserine
concentrations and carcass traits of Angus cattle
HCW2 KPH fat3 Ribeye
area4
Fat
thickness5
Marbling6 Calc YG7
Creatine 0.028 0.035 0.085*** -0.133*** -0.235*** -0.127***
Creatinine 0.085*** -0.091*** -0.083*** 0.284*** 0.082*** 0.271***
Carnosine -0.014 0.143*** 0.013 -0.239*** -0.047* -0.161***
Anserine -0.013 0.162*** 0.043* -0.042 0.013 -0.040
1Pearson correlation coefficients are calculated for HCW, KPH fat, ribeye area, fat thickness, and
calculated yield grades. Spearman correlation coefficients are calculated for marbling scores. Level
of significance: *P<0.05; **P<0.01; ***P<0.001.
2 Hot carcass weight
3Estimated of percentage of kidney, pelvic, and heart fat, % of carcass weight
4Longissimus dorsi cross sectional area at carcass split between the 12th and 13th ribs.
5Measured at 3/4 the lateral distance across the Longissimus dorsi from the spine at carcass split
between the 12th and 13th ribs.
63.0=traces; 4.0=slight; 5.0=small; 6.0=modest; 7.0=moderate; 8.0=slightly abundant; 9.0=moderately
abundant (based on USDA system).
7 Yield grade= 2.5 + (6.35 × fat thickness, cm) + (0.2 × KPH %) + (.0017 ×hot carcass weight, kg) -
(2.06 × ribeye area, cm2)
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GENERAL SUMMARY
Creatine and carnosine are both valuable nutraceuticals that naturally exist only in
animal tissues. Creatine plays an important role in cellular energy metabolism. Mutation in
genes involving creatine biosynthesis and transportation causes an inborn error of
metabolism called creatine deficiency syndromes. Secondary creatine deficiency in brain
cells can be developed by other CNS pathologies, including hyperammonemia, stroke, and
gyrate atrophy of the choroid and retina. Creatine deficiency impairs neurological function.
Recent studies show neuroprotective effects of creatine in neurodegenerative diseases.
Carnosine performs multiple biological functions including pH buffering, anti-oxidation,
anti-glycation, anti-aging, and chelation of divalent metal cations. In humans, creatine and
carnosine can be obtained either endogenously by biosynthesis from primary precursors or
exogenously from dietary sources. Creatinine is the spontaneously formed cyclic derivative
of creatine. Anserine is an N-methylated analogue of carnosine found mainly in fish and
birds. Beef is a good source of dietary creatine and carnosine compared with other meat
products (Hipkiss, 2009; Pais et al., 1999).
In this study, I was interested in determining concentrations of creatine, creatinine,
carnosine, and anserine in longissimus muscle of Angus cattle. An HPLC method was used
to quantify their concentrations in 2,342 beef samples collected from Iowa, Texas, Colorado,
and California. The creatine concentration averaged 5.26 ± 0.01 mg/g, and the carnosine
concentration averaged 3.72 ± 0.01 mg/g. The amount of creatine present in a typical serving
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(100 g) of beef is generally lower than that recommended for supplementation (e.g., a typical
creatine supplement protocol asks for 5 g of creatine per day for four days and then a
maintenance dose of 2 g per day). The carnosine in a typical serving (100 g) of beef is
comparative with the amount in commercial capsule (200-500 mg). We observed significant
gender effects on concentrations of creatine and carnosine. Bulls contained greater creatine
content than did steers (P < 0.05) but produced lower amount of carnosine than did heifers (P
< 0.05).
The correlations among beef creatine, creatinine, carnosine, and anserine with carcass
and palatability traits also were investigated. The weak correlations observed in our study
indicate that beef quality, especially tenderness, juiciness, and flavor would not be strongly
affected by selecting for healthful beef with higher creatine and carnosine contents.
In our study, all beef samples were collected from Angus breed and the harvest ages
were not well documented. In future research, the influences of breed and age could be
further investigated. Besides, the inheritability of these nutraceuticals could be used to study
the influences of genetic factors. The regulation of creatine and carnosine metabolism has not
been well studied. In human, creatine deficiency syndromes are associated with mutations in
AGAT, GAMT, and SLC6A8 genes (Braissant, 2010; Schulze, 2003). Carnosine synthase
was identified as the ATP-grasp domain containing protein 1(ATP-GD 1) very recently
(Drozak et al., 2010). Future studies about genetic factors (especially single polymorphism
nucleotides (SNPs)) associated with the variation of beef creatine, creatinine, carnosine, and
51
anserine could contribute toward revealing the mechanism of creatine and carnosine
homeostasis in both cattle and humans.
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